本文以總結、評析歐洲、中國大陸專利制度中的公序良俗原則為主審視了歐洲、中國大陸對生物技術可專利性的治理模式。這種審視表明唯理主義模式不符合中國大陸的利益需求。中國大陸近期可以參照日本的模式進行初步改革。從遠期看，它應當引進美國的經驗主義模式並完全摒棄歐洲的唯理主義模式。遠期改革需要中國大陸剔除規制生物技術可專利性的唯理主義規範，承認國家專利局復審委員會的復審先例在專利審查實踐中的約束力，承認法院裁判習慣的法律效力。

The article studied the institutional arrangements to define patentable subject matter in the field of biotechnology by generalizing and analyzing the doctrine of ordre public and morality in Europe and Chinese Mainland. It displayed that idealistic arrangements wouldn't accord with utilitarian appeals of Chinese Mainland. In the short run, Chinese Mainland could reform its arranges according to institutional arrangements of Japan. However, it should abolish idealistic arrangements copied from Europe and use empirical ones of the U.S. as references in the long run. Such kinds of arrangements would ask for the abolishment of idealistic norms used to define patentable or unpatentable subject matter. China should also treat decisions of SIPO Board of Appeal as precedents that should be abided by patent examiners and the board itself. On the other hand, it would have to recognize the legal effect of judicial precedents.